SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/R

被引：33

作者：

Sulkowski, M. S. ^{[1
]}

Bourliere, M. ^{[2
]}

Bronowicki, J. -P. ^{[3
]}

Streinu-Cercel, A. ^{[4
]}

Preotescu, L. ^{[4
]}

Asselah, T. ^{[5
]}

Pawlotsky, J. -M. ^{[6
]}

Shafran, S. ^{[7
]}

Pol, S. ^{[8
]}

Caruntu, F. A. ^{[4
]}

Mauss, S. ^{[9
]}

Larrey, D. ^{[10
]}

Haefner, C. ^{[11
]}

Datsenko, Y. ^{[11
]}

Stern, J. O. ^{[12
]}

Kubiak, R. ^{[11
]}

Boecher, W. ^{[11
]}

Steinmann, G. ^{[11
]}

机构：

[1] Johns Hopkins Univ, Baltimore, MD USA

[2] Hop St Joseph, Marseille, France

[3] Hop Brabois, Vandoeuvre Les Nancy, France

[4] Prof Dr Matei Bals Inst Infect Dis, Bucharest, Romania

[5] Hop Beaujon, Clichy, France

[6] Hop Henri Mondor, F-94010 Creteil, France

[7] Univ Alberta, Edmonton, AB, Canada

[8] Hop Cochin, F-75674 Paris, France

[9] Ctr HIV & Hepatogastroenterol, Dusseldorf, Germany

[10] Hop St Eloi, Montpellier, France

[11] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

[12] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA

来源：

JOURNAL OF HEPATOLOGY | 2011年 / 54卷

关键词：

D O I：

10.1016/S0168-8278(11)60068-8

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：S30 / S30

页数：1

共 50 条

[1] SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION
Sulkowski, M. S.
Ceasu, E.
Asselah, T.
Caruntu, F. A.
Lalezari, J.
Ferenci, P.
Streinu-Cercel, A.
Fainboim, H.
Tanno, H.
Preotescu, L.
Leggett, B.
Bessone, F.
Mauss, S.
Stern, J. O.
Haefner, C.
Datsenko, Y.
Nehmiz, G.
Boecher, W.
Steinmann, G.
JOURNAL OF HEPATOLOGY, 2011, 54 : S27 - S27
[2] SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV
Sulkowski, M.
Bourliere, M.
Bronowicki, J. -P.
Streinu-Cercel, A.
Preotescu, L.
Asselah, T.
Pawlotsky, J. -M.
Shafran, S.
Pol, S.
Caruntu, F. A.
Mauss, S.
Larrey, D.
Haefner, C.
Datsenko, Y.
Stern, J.
Kubiak, R.
Steinmann, G.
JOURNAL OF HEPATOLOGY, 2010, 52 : S462 - S463
[3] SILEN-C3: TREATMENT FOR 12 OR 24 WEEKS WITH BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAiVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION
Dieterich, Douglas
Asselah, Tarik
Guyader, Dominique
Berg, Thomas
Ceausu, Emanoil
Preotescu, Liliana
Schuchmann, Marcus
Mauss, Stefan
Ratziu, Vlad
Ferenci, Peter
Larrey, Dominique G.
Maieron, Andreas
Biermer, Michael
Stern, Jerry O.
Scherer, Joe
Kubiak, Rene
Boecher, Wulf O.
HEPATOLOGY, 2011, 54 : 378A - 378A
[4] Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial
Sulkowski, Mark S.
Bourliere, Marc
Bronowicki, Jean-Pierre
Asselah, Tarik
Pawlotsky, Jean-Michel
Shafran, Stephen D.
Pol, Stanislas
Mauss, Stefan
Larrey, Dominique
Datsenko, Yakov
Stern, Jerry O.
Kukolj, George
Scherer, Joseph
Nehmiz, Gerhard
Steinmann, Gerhard G.
Boecher, Wulf O.
HEPATOLOGY, 2013, 57 (06) : 2155 - 2163
[5] VIROLOGICAL RESPONSE AND SAFETY OF BI 201335 PROTEASE INHIBITOR, PEGINTERFERON ALFA 2A AND RIBAVIRIN TREATMENT OF HCV GENOTYPE-1 PATIENTS WITH COMPENSATED LIVER CIRRHOSIS AND NON-RESPONSE TO PREVIOUS PEGINTERFERON RIBAVIRIN
Pol, Stanislas
Berg, Thomas
Bonacini, Maurizio
Schuchmann, Marcus
Lalezari, Jay
Erhardt, Andreas
Bourliere, Marc
Manns, Michael P.
Yong, Chan L.
Steinmann, Gerhard
Stern, Jerry O.
Scherer, Joe
Boecher, Wolf O.
HEPATOLOGY, 2009, 50 (06) : 10A - 11A
[6] SILEN-C1: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAiVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION
Sulkowski, Mark S.
Ferenci, Peter
Emanoil, Ceausu
Asselah, Tarik
Caruntu, Florin
Lalezari, Jay
Bourliere, Marc
Mauss, Stefan
Grange, Jean-Didier
Berg, Thomas
Zeuzem, Stefan
Streinu-Cercel, Adrian
Wright, David
Jensen, Donald M.
Haefner, Carla
Datsenko, Yakiv
Stern, Jerry O.
Nehmiz, Gerhard
Steinmann, Gerhard
HEPATOLOGY, 2009, 50 (06) : 2A - 2A
[7] Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response
Howell, CD
Jeffers, LS
Cassidy, W
Reddy, KR
Hu, S
Lee, JS
JOURNAL OF VIRAL HEPATITIS, 2006, 13 (06) : 371 - 376
[8] A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin
Swain, Mark G.
Lai, Ming-Yang
Shiffman, Mitchell L.
Cooksley, W. Graham E.
Zeuzem, Stefan
Dieterich, Douglas T.
Abergel, Armand
Pessoa, Mario G.
Lin, Amy
Tietz, Andreas
Connell, Edward V.
Diago, Moises
GASTROENTEROLOGY, 2010, 139 (05) : 1593 - 1601
[9] SAFETY AND ANTIVIRAL ACTIVITY OF BI201335, A NEW HCV NS3 PROTEASE INHIBITOR, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTION GIVEN AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA 2A (P) AND RIBAVIRIN (R)
Manns, Michael P.
Bourliere, Marc
Benhamou, Yves
Pol, Stanislas
Bonacini, Maurizio
Berg, Thomas
Trepo, Christian
Wright, David
Steinmann, Gerhard
Huang, David B.
Mikl, Jaromir
Kukolj, George
Stern, Jerry O.
HEPATOLOGY, 2008, 48 (04) : 1133A - 1133A
[10] SAFETY AND ANTIVIRAL ACTIVITY OF BI201335, A NEW HCV NS3 PROTEASE INHIBITOR, IN COMBINATION THERAPY WITH PEGINTERFERON ALFA 2A (P) AND RIBAVIRIN (R) FOR 28 DAYS IN P+R TREATMENT-EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS GENOTYPE-1 INFECTION
Manns, Michael P.
Bourliere, Marc
Benhamou, Yves
Schuchmann, Marcus
Haussinger, Dieter
Pol, Stanislas
Bonacini, Maurizio
Calleja, Jose L.
Steinmann, Gerhard
Huang, David B.
Mikl, Jaromir
Kukolj, George
Stern, Jerry O.
HEPATOLOGY, 2008, 48 (04) : 1151A - 1152A

← 1 2 3 4 5 →